Amirhossein Sahebkar is an Iranian biotechnologist specializing in cardiovascular diseases. He is a faculty member in the department of medical biotechnology at the Mashhad University of Medical Sciences.
Amirhossein Sahebkar | |
|---|---|
امیرحسین صاحبکار | |
| Education | Mashhad University of Medical Sciences (PharmD, PhD) |
| Scientific career | |
| Fields | Medical biotechnology, cardiovascular disease |
| Institutions | Mashhad University of Medical Sciences |
Life
editSahebkar completed a Pharm.D. in 2008 from Mashhad University of Medical Sciences.[1] His dissertation was titled, An investigation of serum antibody titres to heat shock protein 27 (anti- Hsp27) as a biomarker for the detection of acute coronary syndrome.[1] Sahebkar earned a Ph.D. in pharmaceutical biotechnology from the Mashhad University of Medical Sciences. His dissertation was titled, Preparation and evaluation of nanoliposomes conjugated with apolipoprotein B-100 antibodies as a therapeutic option for serum LDL reduction.[1] He completed a postdoctoral fellowship in cardiometabolic diseases at the University of Western Australia.[2]
Sahebkar is a faculty member in the department of medical biotechnology at the Mashhad University of Medical Sciences.[3] His research focuses on cardiovascular disease, atherosclerosis, and blood lipids.[3] He is a member of the Iran's National Elites Foundation.[1] In 2016, he was presented the Professor Dr. Fereydoun Azizi award by the Iranian Academy of Medical Sciences.[3][2]
References
edit- ^ a b c d Sahebkar, Amirhossein. "Resume". USERN. Retrieved 2024-02-17.
- ^ a b "دانشمند برگزیده دهه اخیر کشور در علومپزشکی کیست؟". www.khabaronline.ir (in Persian). 2018-02-02. Retrieved 2024-02-17.
- ^ a b c "انتخاب دکتر صاحبکار بعنوان دانشمند برگزیده دهه اخیر در حوزه علوم پزشکی". ایسنا (in Persian). 2018-02-02. Retrieved 2024-02-17.
.svg){kind=small}  | This Iranian academic-related biographical article is a stub. You can help Wikipedia by expanding it. |